A combination comprising 2 to 8 mg of 5-[4-[2-(N-methyl-N- (2-pyridyl)amino)-ethoxy]benzyl]thiazolidine-24-dione (rosiglitazone) or a tautomeric form thereof or a pharmaceutically acceptable salt or solvate thereof; and sub maximal amount of sulphonylurea selected from glibenclamide glipizide gliclazide tolazamide tolbutamide acetohexamide carbutamide chlorpropamide glibornuride gliquidone glisentide glisolamide glisoxepide glyclopyamide and glycylamide. Disclosed is also a medical use of the co...

Pharmaceutical composition comprising 2 to 8 mg of 5-[4-[2-(N-2-methyl-N-pyridyl)amino)ethoxy]benzyl]tiazolidin-24- dione (rosiglitazone) or a pharmaceutically acceptable salt thereof and a sub-maximal amount of glimepiride. The composition is intended for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in mammals. The invention also relates to the use of the aforementioned pharmaceutical composition.

Pharmaceutical composition suitable for once daily administration which comprises: (a) 2 mg to 12 mg of 5-[4-[2-(N- methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione i. e. rosiglitazone optionally in the form of a pharmaceutically acceptable salt or solvate thereof; (b) 100 mg to 3000 mg of metformin or a pharmaceutically acceptable salt thereof; and (c) a pharmaceutically acceptable carrier; wherein the composition is arranged to provide sustained release of rosiglitazone and metfor...

Pharmaceutical composition for once daily administration wherein the composition is a multi-layered tablet and comprises a) 2 mg to 12 mg of 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione i. e. rosiglitazone optionally in the form of a pharmaceutically acceptable salt ester or solvate thereof; and b) a pharmaceutically acceptable carrier. The composition is arranged so as to provide a combination of non-modified release of rosiglitazone and sustainable release of rosig...

Pharmaceutical composition comprises 2 to 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine- 24-dione i. a. rosiglitazone in the form of a free base or a tautomeric form thereof and/or in the form of a pharmaceutically acceptable derivative and a sulphonylurea preferably glibenclamide glipizide gliclazide glimepiride tolazamide or tolbutamide. Also disclosed is the use of 2 to 8 mg of rosiglitazone and a sulphonylurea for the manufacture of a medicament for the treatment of...

Pharmaceutical composition comprising 2 to 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine- 24-dione i. e. rosiglitazone or a pharmaceutically acceptable form thereof metformin or metformin hydrochloride in an amount up to 3000 mg and a pharmaceutically acceptable carrier. Also disclosed is the use of 2 to 8 mg of rosiglitazone or a pharmaceutically acceptable form thereof and metformin or metformin hydrochloride in an amount up to 3000 mg for the manufacture of a medicam...

A method for the promotion of growth and/or repair of neurons in diseases or conditions characterised by neuron degeneration injury or impaired plasticity which method comprises the administration of an effective non-toxic and pharmaceutically acceptable amount of a PPARgamma agonist or a pharmaceutically acceptable derivative thereof.